Hotspot DNA Methyltransferase 3A (DNMT3A) and Isocitrate Dehydrogenase 1 and 2 (IDH1/2) Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for Immunotherapy
Authors:
- Nadine E. StruckmanNSNadine E. Struckman
- Rob C. M. de JongRJRob C. M. de Jong
- M. Willy HondersMHM. Willy Honders
- Sophie-Anne I. SmithSSSophie-Anne I. Smith
- Dyantha I. van der LeeDLDyantha I. van der Lee
- Georgia KoutsoumpliGKGeorgia Koutsoumpli
- Arnoud H. de RuARArnoud H. de Ru
- Jan-Henrik MikeschJMJan-Henrik Mikesch
- Peter A. van VeelenPVPeter A. van Veelen
- J. H. Frederik FalkenburgJFJ. H. Frederik Falkenburg
- Marieke GriffioenMGMarieke Griffioen
Open Access
- 14 May 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 1086
Abstract
DNA methyltransferase 3A (DNMT3A) and isocitrate dehydrogenase 1 and 2 (IDH1/2) are genes involved in epigenetic regulation, each mutated in 7–23% of patients with acute myeloid leukemia. Here, we investigated whether hotspot mutations in these genes encode neoantigens that can be targeted by immunotherapy. Five human B-lymphoblastoid cell lines expressing common HLA class I alleles were transduced with a minigene construct containing mutations that often occur in DNMT3A or IDH1/2. From these minigene-transduced cell lines, peptides were eluted from HLA class I alleles and analyzed using tandem mass spectrometry. The resulting data are available via ProteomeXchange under the identifier PXD050560. Mass spectrometry revealed an HLA-A*01:01-binding DNMT3AR882H peptide and an HLA-B*07:02-binding IDH2R140Q peptide as potential neoantigens. For these neopeptides, peptide–HLA tetramers were produced to search for specific T-cells in healthy individuals. Various T-cell clones were isolated showing specific reactivity against cell lines transduced with full-length DNMT3AR882H or IDH2R140Q genes, while cell lines transduced with wildtype genes were not recognized. One T-cell clone for DNMT3AR882H also reacted against patient-derived acute myeloid leukemia cells with the mutation, while patient samples without the mutation were not recognized, thereby validating the surface presentation of a DNMT3AR882H neoantigen that can potentially be targeted in acute myeloid leukemia via immunotherapy.Keywords
Funding Information
- KWF Kankerbestrijding (11867, 91116004)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (11867, 91116004)
- LUMC Research Foundation (11867, 91116004)
This publication has 28 references indexed in Scilit:
- T cell receptor therapeutics: immunological targeting of the intracellular cancer proteomeNature Reviews Drug Discovery, 2023
- A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivoNature Cancer, 2023
- Modeling human cancer predisposition syndromes using CRISPR/Cas9 in human cell line modelsGenes, Chromosomes and Cancer, 2023
- Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatmentInternational Journal of Hematology, 2022
- Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigensNature Communications, 2021
- De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017Cancer, 2021
- Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencingLeukemia, 2020
- DNMT3A R882H mutation in acute myeloid leukemia cell line SET-2Leukemia Research, 2020
- RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia MutationsMolecular Therapy Nucleic Acids, 2017
- Accurate quantitation of MHC-bound peptides by application of isotopically labeled peptide MHC complexesJournal of Proteomics, 2014